Biotech Coverage Wave: H.C. Wainwright Reaffirms Buys Across Pharvaris, 4D Molecular, Cytokinetics and CorMedix

A cluster of same-day reiterations from H.C. Wainwright put small- and mid-cap biotech back in focus, with the common thread being idiosyncratic catalysts rather than macro-driven risk appetite. Pharvaris was reaffirmed on regulatory progress, while 4D Molecular Therapeutics retained a Buy rating with a $36 price target. Cytokinetics' rating was maintained against the backdrop of patent litigation, an increasingly material valuation variable as branded franchises defend exclusivity windows. CorMedix was reiterated following what the firm characterized as a strong quarter, evidence that commercial-stage execution is now the differentiating factor within the group. Meanwhile India-listed pharma provided a counterpoint: Alkem Laboratories' first-quarter profit fell and the stock slipped 2.3%, a reminder that generics margin compression remains a global headwind. For institutional investors, the setup argues for barbelling — pairing catalyst-rich clinical names against the structural pricing pressure now visible across commoditized drug manufacturing.